{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:51:26Z","timestamp":1791996686617,"version":"4.4.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bone.2026.118003","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T07:16:31Z","timestamp":1783062991000},"page":"118003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Baseline \u03b2-CTX and BMI predict suitability for deferred zoledronic acid redosing beyond 12\u00a0months in postmenopausal Indian women with osteoporosis"],"prefix":"10.1016","volume":"212","author":[{"given":"Vivek","family":"Jha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay Kumar","family":"Bhadada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soham","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimesh","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Kharbanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bone.2026.118003_bb0005","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2026.118003_bb0010","series-title":"Epidemiology | International Osteoporosis Foundation","author":"International Osteoporosis F","year":"2025"},{"issue":"18","key":"10.1016\/j.bone.2026.118003_bb0015","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.bone.2026.118003_bb0020","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.bone.2026.118003_bb0025","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran","year":"2011","journal-title":"Osteoporos. Int."},{"issue":"2","key":"10.1016\/j.bone.2026.118003_bb0030","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/jbmr.4178","article-title":"Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained","volume":"36","author":"Eastell","year":"2021","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2026.118003_bb0035","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12020-016-0900-2","article-title":"The use of biochemical markers of bone turnover in the clinical management of primary and secondary osteoporosis","volume":"52","author":"Vasikaran","year":"2016","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.bone.2026.118003_bb0040","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2407031","article-title":"Fracture Prevention with Infrequent Zoledronate in Women 50 to 60 Years of Age","volume":"392","author":"Bolland","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bone.2026.118003_bb0045","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1210\/jc.2011-2081","article-title":"Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial","volume":"97","author":"Grey","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2026.118003_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2015.00024","article-title":"Ethnic differences in bone health","volume":"6","author":"Zengin","year":"2015","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"12","key":"10.1016\/j.bone.2026.118003_bb0055","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1007\/s00198-025-07703-x","article-title":"Personalizing denosumab therapy in postmenopausal Indian women with osteoporosis: predictive role of bone turnover markers and body mass index in determining dosing interval","volume":"36","author":"Jha","year":"2025","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2026.118003_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2024.117182","article-title":"Bone turnover markers reference database in five Southeast Asian countries","volume":"187","author":"Lee","year":"2024","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.bone.2026.118003_bb0065","doi-asserted-by":"crossref","first-page":"43","DOI":"10.11005\/jbm.2020.27.1.43","article-title":"Reference Intervals for Bone Turnover Markers in Korean Healthy Women","volume":"27","author":"Cho","year":"2020","journal-title":"J Bone Metab."},{"issue":"2","key":"10.1016\/j.bone.2026.118003_bb0070","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"25","key":"10.1016\/j.bone.2026.118003_bb0075","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","article-title":"Fracture Prevention with Zoledronate in Older Women with Osteopenia","volume":"379","author":"Reid","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.bone.2026.118003_bb0080","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S2213-8587(24)00003-2","article-title":"Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years","volume":"12","author":"Reid","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.bone.2026.118003_bb0085","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11657-025-01588-3","article-title":"The 2024 UK clinical guideline for the prevention and treatment of osteoporosis","volume":"20","author":"Gregson","year":"2025","journal-title":"Arch. Osteoporos."},{"issue":"1","key":"10.1016\/j.bone.2026.118003_bb0090","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"Jama"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226002292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328226002292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:40:54Z","timestamp":1791996054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328226002292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":18,"alternative-id":["S8756328226002292"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2026.118003","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baseline \u03b2-CTX and BMI predict suitability for deferred zoledronic acid redosing beyond 12\u00a0months in postmenopausal Indian women with osteoporosis","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2026.118003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118003"}}